Citation Impact
Citing Papers
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
2008
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
2010
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
2007
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
2011 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Triple-Negative Breast Cancer
2010 Standout
Effect of Time to Resumption of Chemotherapy After Definitive Surgery on Prognosis for Non-Metastatic Osteosarcoma
2009
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma
2011
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
2006
Survival of children with bone sarcoma in Europe since 1978
2001
Anthracycline-Induced Cardiomyopathy
2010
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Osteosarcoma: Review of the Past, Impact on the Future. The American Experience
2009
Protein nanoparticles as drug carriers in clinical medicine
2008
Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment
2005
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
Ovarian cancer
2014 Standout
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
2011
International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience
2009
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
2010
Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma
2013
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Endometriosis
2009 Standout
Osteosarcoma treatment: state of the art
2009
Cancer drug resistance: an evolving paradigm
2013 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial
2002 Standout
Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma
2012
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
The biology and function of fibroblasts in cancer
2016 Standout
Esophageal Cancer
2003 Standout
Neoadjuvant Chemotherapy and Local Radiotherapy for High-Grade Osteosarcoma of the Extremities
2003
Clinico-histologic parameters of osteosarcoma patients with late relapse
2006
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
2009
Osteosarcoma
2010 Standout
Lynch Syndrome Patients with Limited Family History Identified in a Laboratory Setting: A Descriptive Study
2015 Standout
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Frontline treatment of localized osteosarcoma without methotrexate
2011
Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials
2005
Osteosarcoma treatment – Where do we stand? A state of the art review
2013 Standout
Cancer genes and the pathways they control
2004 Standout
Two-Stage Revision for Infected Endoprostheses Used in Tumor Surgery
2002
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ
2009
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Primary bone osteosarcoma in the pediatric age: State of the art
2006
Chemotherapy for Osteosarcoma without High-Dose Methotrexate: A 12-Year Follow-Up on 53 Patients
2007
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Oesophageal carcinoma
2013 Standout
Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project
2006
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Limb salvage in musculoskeletal oncology
2003
Overview of the clinical efficacy of investigational anticancer drugs
2003
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer)*
2007
Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Esophagus
2002
Delaying surgery with chemotherapy for osteosarcoma of the extremities
2004
Osteosarcoma over the age of forty
2002
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Surgical outcomes in osteosarcoma
2002
Survival in high-grade osteosarcoma: improvement over 21 years at a single institution
2009
Management of osteosarcoma
2006
SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients
2007
Treatment of Infections Associated with Surgical Implants
2004 Standout
Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications
2009
Serum protein signature may improve detection of ductal carcinoma in situ of the breast
2009
Preservation of Fertility in Patients with Cancer
2009 Standout
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy
2006
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
2007
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
2013
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
2001
The Epidemiology of Osteosarcoma
2009 Standout
Pan-European Sarcoma Trials: Moving Forward in a Climate of Increasing Economic and Regulatory Pressure
2007
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study
2000
Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13
2005
Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments
2013
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer
2012
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
2014 StandoutNobel
Redefining the Target: Chemotherapeutics as Antiangiogenics
2001
Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report
2000
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
2015
Aromatase Inhibitors in the Treatment of Breast Cancer
2005
Reconstructing the DNA Methylation Maps of the Neandertal and the Denisovan
2014 StandoutScienceNobel
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Breast Cancer Treatment
2019 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
2005
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
2002 Standout
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program
2014
High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma
2004
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
2003
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
EMT, CTCs and CSCs in tumor relapse and drug-resistance
2015
Evolving concepts in the systemic adjuvant treatment of breast cancer.
1992
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
2002 Standout
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2012
Primary Systemic Therapy of Breast Cancer
2006
Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651
2003
Works of M. Nooij being referenced
Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
2008
Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
2006
Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas
2003
Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
2011
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients
2008
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
2003
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
2003
Doxorubicin‐paclitaxel
2002
Survival of Patients with Ovarian Cancer due to a Mismatch Repair Defect
2005
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
1997
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials
2011
“Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
1991
Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup
2007
A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma
1999
Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study
1999
Unstable Preferences:
2000
347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC)
1995
First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group
2004